Harold S. Bernstein's most recent trade in Maze Therapeutics Inc. was a trade of 30,000 Common Stock done at an average price of $10.4 . Disclosure was reported to the exchange on March 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 10 Mar 2026 | 30,000 | 30,000 | - | 10.4 | 312,600 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Mar 2026 | 30,000 | 267,407 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 50.45 per share. | 10 Mar 2026 | 29,652 | 348 | - | 50.4 | 1,495,807 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 51.01 per share. | 10 Mar 2026 | 348 | 0 | - | 51.0 | 17,753 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 02 Feb 2026 | 15,000 | 15,000 | - | 10.4 | 156,300 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2026 | 15,000 | 297,407 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 45.89 per share. | 02 Feb 2026 | 8,364 | 6,036 | - | 45.9 | 383,816 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 46.37 per share. | 02 Feb 2026 | 5,936 | 100 | - | 46.4 | 275,271 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 44.20 per share. | 02 Feb 2026 | 600 | 14,400 | - | 44.2 | 26,523 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 47.23 per share. | 02 Feb 2026 | 100 | 0 | - | 47.2 | 4,723 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 07 Jan 2026 | 25,156 | 25,156 | - | 10.4 | 262,126 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jan 2026 | 25,156 | 312,407 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 40.20 per share. | 07 Jan 2026 | 25,156 | 0 | - | 40.2 | 1,011,299 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 02 Jan 2026 | 4,432 | 4,432 | - | 10.4 | 46,181 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 40.43 per share. | 02 Jan 2026 | 4,432 | 0 | - | 40.4 | 179,188 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 4,432 | 337,975 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Jan 2026 | 412 | 337,563 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 02 Jan 2026 | 412 | 412 | - | 10.4 | 4,293 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 02 Jan 2026 | 412 | 0 | - | 40 | 16,480 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.42 per share. | 29 Dec 2025 | 45,000 | 45,000 | - | 10.4 | 468,900 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2025 | 45,000 | 342,407 | - | - | Stock Option (Right to Buy) | |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 40.34 per share. | 29 Dec 2025 | 27,800 | 17,200 | - | 40.3 | 1,121,424 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Sale of securities on an exchange or to another person at price $ 40.93 per share. | 29 Dec 2025 | 17,200 | 0 | - | 40.9 | 703,931 | Common Stock |
| Maze Therapeutics Inc | Harold S. Bernstein | President, R&D & CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Sep 2025 | 40,000 | 40,000 | - | - | Restricted Stock Units |